Cellular Biomedicine Group (NASDAQ: CBMG) is a biomedicine company principally engaged in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell-based technologies. The company is focused on developing and marketing safe and effective cell-based therapies based on its cellular platforms that represent a large unmet need in China, such as cancer, orthopedic diseases (including osteoarthritis and tissue damage), various inflammatory diseases and metabolic diseases. For more information, visit the company’s website at www.cellbiomedgroup.com.